# 1859

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/1859

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.eighteenfiftynine.com
- Total disclosed funding: $40M
- Latest round: Series A (Nov 17, 2021)
- Investors on record: 4

## About

Based in San Diego, CA, US, and founded in 2019 by Devon Cayera and Andrew MacConnell, 1859, Inc. is a biotechnology company focusing on the discovery and development of next-generation therapeutics. In February 2022, 1859, Inc. raised USD 40 million in series A financing by investors Northpond Ventures, OMX Ventures, FusionX Ventures and Vertical Venture Partners.

The company's platform helps in creating new medicine, enabling scientists to parallelize the discovery of new medicines by combining datasets generated from pico-scale screening of novel chemical libraries with artificial intelligence predictions.

1859, Inc. plans to use the funding to support the development of new capabilities, and the scaling and advancement of preclinical discovery programs building upon a base of 16 pharmaceutical, biotech and academic partners.

## Funding rounds

- Series A, Nov 17, 2021, $40M — Vertical Venture Partners, FusionX Ventures, Northpond Ventures, OMX Ventures

## Investors

- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series A
- FusionX Ventures (https://capitalatlas.ai/funds/fusionx-ventures) — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Series A